Lupin Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Record quarter, powered by U.S. exclusivity: Revenue crossed INR 7,000 cr and EBITDA margin hit 31.3%, a multi-year high, driven by Tolvaptan 180-day exclusivity and new U.S. launches.
• The Tolvaptan tailwind is finite, and the runway is uncertain: Management expects more runway than a typical exclusivity period because competitor TAs are delayed, but the exact duration is unknowable and competition is still expected.
• Margins will normalize downward, and FY27 is guided lower: FY26 EBITDA margin guidance was raised to 25%-26%, but FY27 is guided down to 24%-25% as R&D spend normalizes and the Tolvaptan benefit fades.
• A biosimilar and complex injectable pipeline is being built for the medium term: Five biosimilars are targeted for the U.S. market by FY30, with Pegfilgrastim and Ranibizumab as near-term catalysts, while the business currently burns cash.
• What to watch next quarter: The pace of Tolvaptan revenue erosion as competition enters, the launch trajectory of generic Victoza and Risperdal Consta, and any update on the Nagpur facility's regulatory status.

U.S. Business: The Exclusivity Engine and What Comes After

• Tolvaptan drove the quarter: First-to-file exclusivity on a significant product, combined with launches of Mirabegron and generic Spiriva, produced one of the highest U.S. revenue figures to date, offsetting low single-digit QoQ price erosion in the base portfolio including Albuterol.
• Exclusivity runway is extended but unquantified: Management expects some competition but believes not both anticipated competitors will make it to market, citing delayed TAs with none sighted yet, which should yield more runway than a standard 180-day window.
• Albuterol has stabilized for now: The product has found a floor, but Amneal is expected to enter at some point, which will cause further erosion.
• Spiriva share is stable, but the Medicare unlock is a timing unknown: Share has stabilized, yet access on the Medicare front remains a struggle; the new U.S. administration's focus on biosimilars and generics is a tailwind, but management concedes it is hard to predict when meaningful Medicare access will materialize.
• Mirabegron market dynamics are better than feared: The market has grown and the innovator has retained a good share; earlier guidance may have been conservative, and no new entrants are expected in the near term.
• U.S. revenue guidance: Expected to close over USD 1 billion for the full year, with a Q2 run rate between USD 275 million and USD 300 million per quarter.

Vinita Gupta: "We would expect some competition, but we also believe that the two competitors that we're expecting, not both of them may make it. The TAs are delayed, we don't see any TAs as of yet, so we do think that we are going to get more of a runway."

Margin Trajectory: Peak Now, Normalize Later

• Gross margin surged on mix: The 403 bps YoY improvement was driven by a better product mix, a lower share of in-licensed products, higher profitability on loss-of-exclusivity products in India, increased volumes, and cost improvements.
• EBITDA margin hit a multi-year high of 31.3%: The expansion was driven by higher gross margins and lower fixed costs, with employee expenses rising 9.7% YoY on regular increments and business growth, and other operating income boosted by INR 40 cr from higher PLI export benefits.
• H2 FY26 will be tempered: Margins are expected to moderate in the second half due to higher R&D spends and lower PLI income.
• FY27 margin guidance is a step down to 24%-25%: Management explicitly guided FY27 EBITDA margins below the raised FY26 range of 25%-26%, citing R&D normalization and a sales growth comparison that may be lacklustre versus the current year.
• Gross margin may decline further: Management is working on alternate vendor development to support the gross margin line, but a decline is possible; the 24%-25% EBITDA margin target already embeds that risk, with operating leverage doing the offset work.

India & Branded Markets: Steady, With LOE Noise Clearing

• India domestic formulations grew 8.8% YoY, 1.2x IPM: The overall India number was moderated by lower local tender sales in the Global Institutional business; excluding the loss of exclusivity on Gibtulio and Ajaduo, domestic growth stood at 10.7% YoY for H1.
• Therapy-level momentum is strong: GI grew at 6x its category rate; Cardiac and Respiratory each grew at 1.5x their respective category averages, supported by strong volume growth.
• The LOE drag is now done: From H2 onwards, the India business is normalized with the LOE effect fully behind it.
• Other Developed markets were led by Europe at 26.8% YoY: Growth came from higher sales in Germany and the UK on existing products and partner sales, with Luforbec continuing as a strong performer and Raltegravir contributing well.
• Emerging markets grew 45% YoY, led by Brazil at 141% in local currency: The Brazil turnaround was aided by successful diabetes product launches including Dapagliflozin, with Empagliflozin approval received this week; South Africa also turned around after restructuring its portfolio.
• Europe ambition is to sustain 20%+ growth: Management expects Europe to grow higher than the company average on a three-to-five-year basis, with the VISUfarma acquisition adding Italy and Spain to the footprint.

Pipeline & Complex Products: The Medium-Term Pivot

• Complex injectables are arriving now: Lupin became the first Indian company to secure approval for generic Victoza, received approval for Risperdal Consta (its first from the Nanomi platform), and obtained a Glucagon approval; Risperdal Consta is about to launch in the next couple of weeks.
• Biosimilars are a five-product, FY30 ambition: The target is at least five products in the U.S. market by FY30: Pegfilgrastim (goal date end of this month), Ranibizumab (first prefilled syringe filed, goal date middle of next year), on-body Pegfilgrastim (third to market), Eylea (FY28/FY29), and Etanercept (FY29 due to submarine patent).
• The biosimilar business is currently a cash burn, but not hugely so: Management acknowledged the portfolio is negative today but expects it to turn positive in the next couple of years; no quantification of the annual burn was provided.
• Ranibizumab is a particularly interesting opportunity: It is the first prefilled syringe filed in the U.S., and the two existing biosimilars on the market are currently out of the market, presumably due to pricing concerns, creating a potential opening.
• Respiratory pipeline is deep but filing timelines are back-end loaded: Dulera has been filed and the CRL responded to; Spiriva Respimat filing dates are hoped to be concretized by end of this fiscal year; the Ellipta franchise (Breo, Trelegy, Anoro) and Trimbow are under development; green propellant versions for U.S. products are in development.
• Green propellant is a strategic differentiator: The UK has set a definitive date to discontinue high-carbon-footprint propellants, Europe will follow, and the U.S. will be third; Lupin sees an opportunity to differentiate products like Xopenex where the brand does not transition, and to sustain its respiratory franchise growth.
• Peptide capability is being built in-house: Semaglutide and Tirzepatide are in the works, with in-house peptide capability expanding significantly; Semaglutide is expected to go generic starting next year in India and a few other markets, with India as the key near-term market and South Africa next year.

Vinita Gupta: "I feel pretty good about that one because I think they're the first prefilled syringe filed in the U.S. Also, currently, the two biosimilars that were on the market are out of the market. Presumably because of pricing concerns and probably will come in at a different price point. So, that presents a really nice opportunity."

Capital Allocation & Strategic Moves

• VISUfarma acquisition adds ophthalmology and European breadth: Lupin is under-indexed in Europe; VISUfarma brings 60+ innovative eye health products and adds Italy and Spain to the existing UK, Germany, and France presence, with expected close by 2025 and a path to USD 150 million in annualized global specialty revenues next year.
• Coral Springs investment is a USD 250 million respiratory bet: The planned U.S. facility will house Respimat and Ellipta franchise capacity plus an MDI line for government business access and risk diversification; the Ellipta line carries marginal cost difference versus India but offers the advantage of manufacturing close to the R&D site.
• Specialty focus is narrowing to three therapy areas: Respiratory, Neurology/CNS (NaMuscla, DM indications, global DM1/DM2 clinical trial), and Ophthalmology (VISUfarma as a starting point, with intent to build further in the U.S. and Europe).
• R&D spend is guided to 7.5%-8.5% of revenue for the full year: An increasing share is expected to flow into specialty programs and value-added medicines including long-acting injectables, green propellant-based products, and 505(b)(2)s.

Vinita Gupta: "We have always said that we are under-indexed in Europe and we have significant potential headroom there but didn't have the right market presence. We had presence in UK, Germany and France very recently. This adds Italy and Spain to us."

Regulatory & Compliance

• Pithampur Unit 3 received VAI status: The respiratory facility was classified as Voluntary Action Indicated, a positive step for the site's regulatory standing.
• Nagpur facility inspection yielded observations management is not happy with: Management believes the observations are addressable and is putting its best foot forward with the response, hoping it will suffice.
• Unit 2 remains under OAI status: The company is actively addressing the Official Action Indicated classification and states it is fully committed to ensuring all sites adhere to the highest global quality and regulatory standards.

Nilesh Gupta: "We're not happy with the observations, but we believe that they are addressable. We're obviously putting our best foot forward at this point of time with the response. And we hope that it will suffice."

Guidance & Commitments

Key Metrics